PLSE
vs
S&P 500
PLSE
S&P 500
Over the past 12 months, PLSE has underperformed S&P 500, delivering a return of -12% compared to the S&P 500's +14% growth.
Stocks Performance
PLSE vs S&P 500
Performance Gap
PLSE vs S&P 500
Performance By Year
PLSE vs S&P 500
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
Pulse Biosciences Inc
Glance View
Pulse Biosciences Inc. operates at the intriguing intersection of healthcare innovation and cutting-edge technology, focusing on the development and commercialization of their proprietary Nano-Pulse Stimulation (NPS) technology. NPS is a novel bio-electrical platform designed to deliver ultra-short electrical pulses designed to induce cell stress and modify cell structure without significantly impacting non-cellular structural elements. The company primarily concentrates on medical applications that demand precision and safety, notably in dermatology, oncology, and other critical therapeutic areas. By developing devices like the CellFX System, Pulse Biosciences allows physicians to treat conditions with minimal invasiveness, offering alternatives to traditional methods like surgery. Pulse Biosciences generates revenue by selling these medical devices and fostering strategic partnerships within the healthcare sector to expand the application and adoption of NPS technology. The company's business model hinges on convincing healthcare professionals and institutions of the tangible benefits and potential cost savings that their innovative solutions offer. By aligning themselves with clinicians and medical researchers, Pulse Biosciences endeavors to expand the clinical indications for NPS technology, gradually scaling their market presence. Although the journey involves navigating the complex regulatory landscape and proof of clinical efficacy, the company aims to sustain growth through continuous innovation and market expansion, targeting widespread adoption of their groundbreaking platforms.
